The SARS-CoV-2–neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine
- 20 September 2021
- journal article
- letter
- Published by Elsevier BV in Kidney International
- Vol. 100 (5), 1129-1131
- https://doi.org/10.1016/j.kint.2021.09.006
Abstract
No abstract availableFunding Information
- Novo Nordisk Fonden (NNF20SA0062931)
This publication has 4 references indexed in Scilit:
- Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patientsScience Immunology, 2021
- Negative SARS-CoV-2 antibodies, T-cell response and virus neutralization following full vaccination in a renal transplant recipient: a call for vigilanceClinical Microbiology & Infection, 2021
- Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapyKidney International, 2021
- Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccineKidney International, 2021